We are developing Memtin™ to treat Leptin deficiency in Alzheimer’s patients. This Leptin product will act as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2005
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Mmetin
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
